MedTrace Logo

Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia

NCT00493545 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-05-07

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of HspE7 and Poly-ICLC when given together

Conditions

  • Cervical Intraepithelial Neoplasia

Interventions

BIOLOGICAL

HspE7 and Poly-ICLC

3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections

Sponsors & Collaborators

  • Nventa Biopharmaceuticals Corporation

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493545 on ClinicalTrials.gov